Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Assets (2019 - 2025)

Historic Assets for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $1.7 billion.

  • Legend Biotech's Assets fell 131.79% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year decrease of 131.79%. This contributed to the annual value of $1.7 billion for FY2024, which is 965.35% down from last year.
  • Legend Biotech's Assets amounted to $1.7 billion in Q3 2025, which was down 131.79% from $1.7 billion recorded in Q2 2025.
  • Legend Biotech's 5-year Assets high stood at $875.1 billion for Q2 2021, and its period low was $813.8 million during Q3 2021.
  • Moreover, its 5-year median value for Assets was $1.7 billion (2025), whereas its average is $89.0 billion.
  • Data for Legend Biotech's Assets shows a peak YoY increase of 5503.06% (in 2021) and a maximum YoY decrease of 9988.52% (in 2021) over the last 5 years.
  • Over the past 5 years, Legend Biotech's Assets (Quarter) stood at $1.1 billion in 2021, then rose by 18.89% to $1.3 billion in 2022, then soared by 38.89% to $1.8 billion in 2023, then fell by 9.65% to $1.7 billion in 2024, then increased by 2.56% to $1.7 billion in 2025.
  • Its last three reported values are $1.7 billion in Q3 2025, $1.7 billion for Q2 2025, and $1.6 billion during Q1 2025.